Clinical Trial Suggests Soliris Could be an Effective Treatment for Neuromyelitis Optica Spectrum Disorders
According to a story from BusinessWire, the drug developer Alexion Pharmaceuticals, Inc., recently announced positive results for its Phase 3 trial testing Soliris as a therapy for neuromyelitis optica spectrum…